Kronos Bio and Invivoscribe Partner on Companion Diagnosticmarketing2022-08-22T21:30:25+00:00August 16th, 2022|2022 Press Releases, Press Releases|更多详细信息
Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicinewmm2022-05-11T14:41:48+00:00May 9th, 2022|2022 Press Releases, Press Releases|更多详细信息
Roswell Park综合癌症中心授权Invvivoscribe的LymphoTrack软件即插即用管道使用 2021年9月2日|2021年新闻发布，新闻发布marketing2021-12-19T07:18:11+00:00September 2nd, 2021|2021 Press Releases, Press Releases|更多详细信息
Invivoscribe宣布向欧盟递交关键申报资料，扩大在中国的影响力和活动 2021年7月22日|2021年新闻发布，新闻稿marketing2021-12-19T07:20:17+00:00July 22nd, 2021|2021 Press Releases, Press Releases|更多详细信息
Invivoscribe启动资助计划，支持基于序列的免疫系统分析新应用 2021年6月24日wmm2021-12-19T07:20:24+00:00June 24th, 2021|2021 Press Releases, Press Releases|更多详细信息
在美国、欧洲和中国，Invivoscribe在其设立的参考实验室首次推出12色流式细胞术检测 2021年6月3日|2021年新闻发布，新闻稿wmm2021-12-19T07:20:31+00:00June 3rd, 2021|2021 Press Releases, Press Releases|更多详细信息
Kronos Bio and Invivoscribe Partner on Companion Diagnosticmarketing2022-08-22T21:30:25+00:00August 16th, 2022|2022 Press Releases, Press Releases|更多详细信息
Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicinewmm2022-05-11T14:41:48+00:00May 9th, 2022|2022 Press Releases, Press Releases|更多详细信息
Roswell Park综合癌症中心授权Invvivoscribe的LymphoTrack软件即插即用管道使用 2021年9月2日|2021年新闻发布，新闻发布marketing2021-12-19T07:18:11+00:00September 2nd, 2021|2021 Press Releases, Press Releases|更多详细信息
Invivoscribe宣布向欧盟递交关键申报资料，扩大在中国的影响力和活动 2021年7月22日|2021年新闻发布，新闻稿marketing2021-12-19T07:20:17+00:00July 22nd, 2021|2021 Press Releases, Press Releases|更多详细信息
Invivoscribe启动资助计划，支持基于序列的免疫系统分析新应用 2021年6月24日wmm2021-12-19T07:20:24+00:00June 24th, 2021|2021 Press Releases, Press Releases|更多详细信息
在美国、欧洲和中国，Invivoscribe在其设立的参考实验室首次推出12色流式细胞术检测 2021年6月3日|2021年新闻发布，新闻稿wmm2021-12-19T07:20:31+00:00June 3rd, 2021|2021 Press Releases, Press Releases|更多详细信息
Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemiamarketing2021-02-26T19:09:41+00:00July 14th, 2020|2020 Press Releases, Press Releases|更多详细信息
Invivoscribe宣布FDA批准的LeukoStrat CDx FLT3突变试剂盒作为IVD试剂盒在美国销售marketing2022-01-03T02:51:13+00:00May 19th, 2020|2020 Press Releases, Press Releases|更多详细信息
Invivoscribe在中国向NMPA提交LeukoStrat®CDx FLT3突变检测，并扩大公司规模，在上海增加实验室，为合作伙伴提供全面支持。marketing2022-01-03T02:51:34+00:00May 12th, 2020|2020 Press Releases, Press Releases|更多详细信息
欧盟委员会批准安斯泰来(Astellas)的XOSPATA，用于经验证试验检测出FLT3突变的复发或难治性急性髓系白血病患者，包括Invivoscribe LeukoStrat CDx FLT3突变检测试剂盒marketing2022-01-03T02:51:42+00:00December 5th, 2019|2019 Press Releases, Press Releases|更多详细信息
日本MHLW批准Invivoscribe公司的LeukoStrat CDx FLT3突变试剂盒作为第一三共制药公司的Quizartinib的伴随诊断，用于复发/难治性FLT3-ITD AML的治疗。 扩展使用包括收集在EDTA的样本marketing2022-01-03T02:51:50+00:00June 19th, 2019|2019 Press Releases, Press Releases|更多详细信息
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignanciesmarketing2021-02-26T19:10:45+00:00May 21st, 2019|2019 Press Releases, Press Releases|更多详细信息
Invivoscribe将在2019年旧金山生物技术展示™上发表演讲wmm2022-01-03T02:52:03+00:00January 3rd, 2019|2019 Press Releases, Press Releases|更多详细信息
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the USInvivoscribe also Receives National Reimbursement for CDx Assay in Japanmarketing2021-02-26T19:11:02+00:00November 29th, 2018|2018 Press Releases, Press Releases|更多详细信息
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinibmarketing2021-02-26T19:11:39+00:00November 19th, 2018|2018 Press Releases, Press Releases|更多详细信息
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japanmarketing2021-02-26T19:11:48+00:00November 19th, 2018|2018 Press Releases, Press Releases|更多详细信息
Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)marketing2021-02-26T19:12:02+00:00September 27th, 2018|2018 Press Releases, Press Releases|更多详细信息
Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panelsmarketing2021-02-26T19:12:15+00:00May 9th, 2018|2018 Press Releases, Press Releases|更多详细信息
Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutationsmarketing2021-02-26T19:12:23+00:00May 8th, 2018|2018 Press Releases, Press Releases|更多详细信息
Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Softwarewmm2021-02-26T19:12:40+00:00November 7th, 2017|2017 Press Releases, Press Releases|更多详细信息
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.wmm2021-02-26T19:12:46+00:00August 1st, 2017|2017 Press Releases, Press Releases|更多详细信息
FDA approves new combination treatment for acute myeloid leukemiawmm2021-02-26T19:12:55+00:00April 28th, 2017|2017 Press Releases, Press Releases|更多详细信息
Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AMLwmm2021-02-26T19:13:02+00:00April 28th, 2017|2017 Press Releases, Press Releases|更多详细信息
Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapieswmm2021-02-26T19:13:49+00:00March 28th, 2017|2017 Press Releases, Press Releases|更多详细信息
Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Softwarewmm2021-02-26T19:13:58+00:00February 28th, 2017|2017 Press Releases, Press Releases|更多详细信息
Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kitswmm2021-02-26T19:14:04+00:00February 14th, 2017|2017 Press Releases, Press Releases|更多详细信息
Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kitswmm2021-02-26T19:14:11+00:00January 31st, 2017|2017 Press Releases, Press Releases|更多详细信息
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosiswmm2021-02-26T19:14:23+00:00November 14th, 2016|2016 Press Releases, Press Releases|更多详细信息
Ion Torrent Developers Alliance Program Designed to Speed Targeted NGS Assay Developmentwmm2021-02-26T19:14:30+00:00May 31st, 2016|2016 Press Releases, Press Releases|更多详细信息
German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Positionwmm2021-02-26T19:14:37+00:00March 28th, 2016|2016 Press Releases, Press Releases|更多详细信息
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)wmm2021-02-26T19:14:49+00:00February 18th, 2016|2016 Press Releases, Press Releases|更多详细信息
Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientificwmm2021-02-26T19:15:19+00:00February 9th, 2016|2016 Press Releases, Press Releases|更多详细信息
Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutationswmm2021-02-26T19:16:48+00:00December 5th, 2015|Archived Press Releases, Press Releases|更多详细信息
Kronos Bio and Invivoscribe Partner on Companion Diagnosticmarketing2022-08-22T21:30:25+00:00August 16th, 2022|2022 Press Releases, Press Releases|更多详细信息
Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicinewmm2022-05-11T14:41:48+00:00May 9th, 2022|2022 Press Releases, Press Releases|更多详细信息
Roswell Park综合癌症中心授权Invvivoscribe的LymphoTrack软件即插即用管道使用 2021年9月2日|2021年新闻发布，新闻发布marketing2021-12-19T07:18:11+00:00September 2nd, 2021|2021 Press Releases, Press Releases|更多详细信息
Invivoscribe宣布向欧盟递交关键申报资料，扩大在中国的影响力和活动 2021年7月22日|2021年新闻发布，新闻稿marketing2021-12-19T07:20:17+00:00July 22nd, 2021|2021 Press Releases, Press Releases|更多详细信息
Invivoscribe启动资助计划，支持基于序列的免疫系统分析新应用 2021年6月24日wmm2021-12-19T07:20:24+00:00June 24th, 2021|2021 Press Releases, Press Releases|更多详细信息
在美国、欧洲和中国，Invivoscribe在其设立的参考实验室首次推出12色流式细胞术检测 2021年6月3日|2021年新闻发布，新闻稿wmm2021-12-19T07:20:31+00:00June 3rd, 2021|2021 Press Releases, Press Releases|更多详细信息
Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemiamarketing2021-02-26T19:09:41+00:00July 14th, 2020|2020 Press Releases, Press Releases|更多详细信息
Invivoscribe宣布FDA批准的LeukoStrat CDx FLT3突变试剂盒作为IVD试剂盒在美国销售marketing2022-01-03T02:51:13+00:00May 19th, 2020|2020 Press Releases, Press Releases|更多详细信息
Invivoscribe在中国向NMPA提交LeukoStrat®CDx FLT3突变检测，并扩大公司规模，在上海增加实验室，为合作伙伴提供全面支持。marketing2022-01-03T02:51:34+00:00May 12th, 2020|2020 Press Releases, Press Releases|更多详细信息
欧盟委员会批准安斯泰来(Astellas)的XOSPATA，用于经验证试验检测出FLT3突变的复发或难治性急性髓系白血病患者，包括Invivoscribe LeukoStrat CDx FLT3突变检测试剂盒marketing2022-01-03T02:51:42+00:00December 5th, 2019|2019 Press Releases, Press Releases|更多详细信息
日本MHLW批准Invivoscribe公司的LeukoStrat CDx FLT3突变试剂盒作为第一三共制药公司的Quizartinib的伴随诊断，用于复发/难治性FLT3-ITD AML的治疗。 扩展使用包括收集在EDTA的样本marketing2022-01-03T02:51:50+00:00June 19th, 2019|2019 Press Releases, Press Releases|更多详细信息
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignanciesmarketing2021-02-26T19:10:45+00:00May 21st, 2019|2019 Press Releases, Press Releases|更多详细信息
Invivoscribe将在2019年旧金山生物技术展示™上发表演讲wmm2022-01-03T02:52:03+00:00January 3rd, 2019|2019 Press Releases, Press Releases|更多详细信息
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the USInvivoscribe also Receives National Reimbursement for CDx Assay in Japanmarketing2021-02-26T19:11:02+00:00November 29th, 2018|2018 Press Releases, Press Releases|更多详细信息
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinibmarketing2021-02-26T19:11:39+00:00November 19th, 2018|2018 Press Releases, Press Releases|更多详细信息
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japanmarketing2021-02-26T19:11:48+00:00November 19th, 2018|2018 Press Releases, Press Releases|更多详细信息
Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)marketing2021-02-26T19:12:02+00:00September 27th, 2018|2018 Press Releases, Press Releases|更多详细信息
Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panelsmarketing2021-02-26T19:12:15+00:00May 9th, 2018|2018 Press Releases, Press Releases|更多详细信息
Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutationsmarketing2021-02-26T19:12:23+00:00May 8th, 2018|2018 Press Releases, Press Releases|更多详细信息
Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Softwarewmm2021-02-26T19:12:40+00:00November 7th, 2017|2017 Press Releases, Press Releases|更多详细信息
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.wmm2021-02-26T19:12:46+00:00August 1st, 2017|2017 Press Releases, Press Releases|更多详细信息
FDA approves new combination treatment for acute myeloid leukemiawmm2021-02-26T19:12:55+00:00April 28th, 2017|2017 Press Releases, Press Releases|更多详细信息
Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AMLwmm2021-02-26T19:13:02+00:00April 28th, 2017|2017 Press Releases, Press Releases|更多详细信息
Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapieswmm2021-02-26T19:13:49+00:00March 28th, 2017|2017 Press Releases, Press Releases|更多详细信息
Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Softwarewmm2021-02-26T19:13:58+00:00February 28th, 2017|2017 Press Releases, Press Releases|更多详细信息
Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kitswmm2021-02-26T19:14:04+00:00February 14th, 2017|2017 Press Releases, Press Releases|更多详细信息
Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kitswmm2021-02-26T19:14:11+00:00January 31st, 2017|2017 Press Releases, Press Releases|更多详细信息
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosiswmm2021-02-26T19:14:23+00:00November 14th, 2016|2016 Press Releases, Press Releases|更多详细信息
Ion Torrent Developers Alliance Program Designed to Speed Targeted NGS Assay Developmentwmm2021-02-26T19:14:30+00:00May 31st, 2016|2016 Press Releases, Press Releases|更多详细信息
German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Positionwmm2021-02-26T19:14:37+00:00March 28th, 2016|2016 Press Releases, Press Releases|更多详细信息
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)wmm2021-02-26T19:14:49+00:00February 18th, 2016|2016 Press Releases, Press Releases|更多详细信息
Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientificwmm2021-02-26T19:15:19+00:00February 9th, 2016|2016 Press Releases, Press Releases|更多详细信息
Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutationswmm2021-02-26T19:16:48+00:00December 5th, 2015|Archived Press Releases, Press Releases|更多详细信息
